Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 291

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 291
---
 claim for the payment of the said unshipped minimum purchase                    
 commitments lacks any ground under the terms of the Framework Supply Agreement and moreover, that the Company was never served with     
 German judicial documents (e.g., statement of claim) of CSL with translations in Hebrew, English or Arabic, as required under the       
 applicable German and international rules of proceeding. Consequently, based on advice of a German legal counsel, the Company are       
 in the opinion that the legal proceeding initiated by CSL suffered a fundamental and material procedural error and that no enforceable  
 German judgement could derive thereto. In 2024, the Company has initiated a proceeding in Germany to annul said German court’s          
 purported ruling.                                                                                                                       |

<div align='center'>F-38</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES 
 (Cont.)                       |

The Company’s product has yet to
be approved by FDA and is still in clinical trials and in any event, is not using CSL’s fibrinogen.

From time to time, the Company has been
and may be in the future subject to other legal proceedings, claims, investigations, and government inquiries (collectively, “Legal
Proceedings”) in the ordinary course of business. There are no currently pending legal proceedings that the Company believes will
have a material adverse impact on the business or financial statements.

| NOTE 10:- | TEMPORARY EQUITY |

The preferred shares confer upon their
holders all rights accruing to holders of ordinary shares (as detailed below in this Note 10) in the Company, and, in addition, the rights,
preferences and privileges granted to the preferred shares as follows:

| A. | Dividends and Other 
 Distributions       |

The holders of all convertible preferred
shares shall be entitled to receive, when and if declared by the board of directors, a noncumulative dividend. Such dividends will be
distributed to the holders of the ordinary shares and the preferred shares on a pro-rata basis. No dividends have been declared to date.

Other distributions described in Company’s
AOA as follows: If the Company shall declare a distribution payable in securities of other persons, evidences of indebtedness issued
by the Company or other persons, assets (excluding cash dividends) or options or rights, or if the Company at any time shall pay a dividend
payable in